{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-042741","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.467888+00:00","generated_at":"2026-05-30T09:03:35.549182+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan","bullets":["Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.","NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.","CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.","Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.","Goodwill of $5.38M recorded; intangible assets amortized over 18 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-042741","json":"https://secwatch.observer/filing/0001493152-24-042741.json","markdown":"https://secwatch.observer/filing/0001493152-24-042741.md","text":"https://secwatch.observer/filing/0001493152-24-042741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/0001493152-24-042741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:03:35.549182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}